Exparel gets FDA go-ahead for pain relief post-shoulder surgery
The US Food and Drug Administration (FDA) has approved a supplemental new drug application for bupivacaine liposomal injectable suspension (Exparel, Pacira Pharmaceuticals Inc) for use as an interscalene brachial plexus nerve block to provide regional analgesia following shoulder surgery in adults.
Read the full story.
Create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies